OPEN END TURBO LONG - HALEON Share Price

Certificat

DE000MD7S4Y8

Delayed Börse Stuttgart 07:27:33 05/06/2024 pm IST
0.92 EUR +2.22% Intraday chart for OPEN END TURBO LONG - HALEON
Current month+1.12%
1 month-7.22%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
05/24/05 0.92 +2.22%
04/24/04 0.9 -3.23%
03/24/03 0.93 +4.49%
31/24/31 0.89 -2.20%
30/24/30 0.91 +4.60%

Delayed Quote Börse Stuttgart

Last update June 05, 2024 at 07:27 pm IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying HALEON PLC
Issuer Morgan Stanley
WKN MD7S4Y
ISINDE000MD7S4Y8
Date issued 01/09/2022
Strike 248.7 p
Maturity Unlimited
Parity 1 : 1
Emission price 0.47
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.45
Lowest since issue 0.27

Company Profile

Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Sector
-
More about the company

Ratings for Haleon plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Haleon plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.227 GBP
Average target price
3.62 GBP
Spread / Average Target
+12.18%
Consensus